Neuren Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Neuren Pharmaceuticals has a total shareholder equity of A$205.2M and total debt of A$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are A$248.0M and A$42.8M respectively. Neuren Pharmaceuticals's EBIT is A$199.2M making its interest coverage ratio -35. It has cash and short-term investments of A$228.5M.
Key information
0%
Debt to equity ratio
AU$0
Debt
Interest coverage ratio | -35x |
Cash | AU$228.54m |
Equity | AU$205.21m |
Total liabilities | AU$42.76m |
Total assets | AU$247.97m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: NEU's short term assets (A$247.2M) exceed its short term liabilities (A$42.8M).
Long Term Liabilities: NEU has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: NEU is debt free.
Reducing Debt: NEU has not had any debt for past 5 years.
Debt Coverage: NEU has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: NEU has no debt, therefore coverage of interest payments is not a concern.